|Dr. Paul A. Friedman||Chairman & CEO||721.17k||N/A||1943|
|Dr. Rebecca A. Taub||Founder, Pres of R&D & Director||610.75k||N/A||1952|
|Mr. Marc R. Schneebaum||Sr. VP & CFO||617.9k||1.6M||1954|
|Mr. Brian J. Lynch||Sr. VP & Gen. Counsel||N/A||N/A||1961|
|Mr. Thomas W. Hare||Sr. VP of Clinical Management||N/A||N/A||N/A|
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 8; Compensation: 6.